Key precautions include monitoring for somnolence, weight loss, hematologic abnormalities, withdrawal risks, phenylketonuria (PKU), and suicidality.  

Clinical Monitoring and Risk Mitigation  

Somnolence (67% incidence) necessitates clobazam dose reduction (25% initially) and avoidance of CNS depressants. Weight/appetite decline requires growth monitoring in pediatric patients. Neutropenia (<1,500/mm³) and thrombocytopenia (<150,000/μL) warrant baseline and biannual blood counts. Abrupt discontinuation risks status epilepticus; gradual withdrawal is critical. PKU patients must avoid oral suspension (contains phenylalanine). Suicidal ideation monitoring is mandated per FDA warnings for all AEDs. Concomitant CYP3A4/CYP2C19 inducers (e.g., carbamazepine) may necessitate DIACOMIT dose adjustments.